A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

• Status: Completed
• Trial end date: 1969-12-31

Summary

A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.

• Phase: Phase 4

Details

• Lead Sponsor: Bukwang Pharmaceutical
• Treatments: Adefovir; Adefovir dipivoxil; Antiviral Agents; Clevudine